N-acyldopamines control striatal input terminals via novel ligand-gated cation channels

Neuropharmacology

Volumn 56, Issue 3, 2009, Pages 676-683

  Ferreira, Samira G ^a   Lomaglio, Tonia ^a   Avelino, Antonio ^b,c   Cruz, Francisco ^b,d   Oliveira, Catarina R ^a   Cunha, Rodrigo A ^a   Köfalvi, Attila ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Ca2+ entry; Cannabinoid; Dopamine release; Glutamate release; N acyldopamines; Striatum; TRPV1 vanilloid receptor

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 AMINOETHOXYDIPHENYLBORANE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; ANANDAMIDE; BORANE DERIVATIVE; CALCIUM ION; CAPSAICIN; CAPSAZEPINE; CATION CHANNEL; DOPAMINE DERIVATIVE; GADOLINIUM; GLUTAMIC ACID; IONOTROPIC RECEPTOR; LIGAND GATED CATION CHANNEL; N ACYLDOPAMINE DERIVATIVE; NICOTINE; OLEOYLDOPAMINE; PALMITOYLDOPAMINE; POTASSIUM ION; UNCLASSIFIED DRUG; VANILLOID 1 RECEPTOR AGONIST; VANILLOID 1 RECEPTOR ANTAGONIST; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RAT;

ANIMALS; ARACHIDONIC ACIDS; BORON COMPOUNDS; CAPSAICIN; CATIONS; CORPUS STRIATUM; DOPAMINE; GLUTAMIC ACID; ION CHANNELS; LIGANDS; MALE; MICE; MICE, MUTANT STRAINS; POLYUNSATURATED ALKAMIDES; PRESYNAPTIC TERMINALS; RATS; RATS, WISTAR; SYNAPTOSOMES; TRPV CATION CHANNELS;

EID: 58749097218     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.12.001     Document Type: Article

References (46)

1. 1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch. Pharmacol. 373 (2006) 287-299
2. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., and Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
3. Chu C.J., Huang S.M., De Petrocellis L., Bisogno T., Ewing S.A., Miller J.D., Zipkin R.E., Daddario N., Appendino G., Di Marzo V., and Walker J.M. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J. Biol. Chem. 278 (2003) 13633-13639
4. Cristino L., de Petrocellis L., Pryce G., Baker D., Guglielmotti V., and Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139 (2006) 1405-1415
5. Czirják G., and Enyedi P. Ruthenium red inhibits TASK-3 potassium channel by interconnecting glutamate 70 of the two subunits. Mol. Pharmacol. 63 (2003) 646-652
6. de Lago E., de Miguel R., Lastres-Becker I., Ramos J.A., and Fernández-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res. 1007 (2004) 152-159
7. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
8. Di Marzo V., Lastres-Becker I., Bisogno T., De Petrocellis L., Milone A., Davis J.B., and Fernandez-Ruiz J.J. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur. J. Pharmacol. 420 (2001) 123-131
9. Docherty R.J., Yeats J.C., and Piper A.S. Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture. Br. J. Pharmacol. 121 (1997) 1461-1467
10. Gill C.H., Randall A., Bates S.A., Hill K., Owen D., Larkman P.M., Cairns W., Yusaf S.P., Murdock P.R., Strijbos P.J., Powell A.J., Benham C.D., and Davies C.H. Characterization of the human HCN1 channel and its inhibition by capsazepine. Br. J. Pharmacol. 143 (2004) 411-421
11. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260 (1985) 3440-3450
12. + currents in rat cultured striatal neurons. Pflugers Arch. 434 (1997) 642-645
13. 3. J. Biol. Chem. 279 (2004) 35741-35748
14. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza F., Tognetto M., Petros T.J., Krey J.F., Chu C.J., Miller J.D., Davies S.N., Geppetti P., Walker J.M., and Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 8400-8405
15. 1 phosphorylation in sensory neurons. J. Biol. Chem. 281 (2006) 32879-32890
16. Köfalvi A. Alternative interacting sites and novel receptors for cannabinoid ligands. In: Köfalvi A. (Ed). Cannabinoids and the Brain (2008), Springer US 131-160
17. 1 vanilloid receptors in rat hippocampal nerve terminals. Neurosci. Lett. 403 (2006) 151-156
18. Köfalvi A., Rodrigues R.J., Ledent C., Mackie K., Vizi E.s., Cunha R.A., and Sperlágh B. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J. Neurosci. 25 (2005) 2874-2884
19. 2+ levels and transmitter release in the hippocampus. Br. J. Pharmacol. 151 (2007) 551-563
20. q/11 G proteins. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 19144-19149
21. 2 and is blocked by gadolinium. Eur. J. Neurosci. 26 (2007) 12-22
22. Liu L., and Simon S.A. Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia. Neurosci. Lett. 228 (1997) 29-32
23. Lovinger D.M. Presynaptic modulation by endocannabinoids. Handb. Exp. Pharmacol. 184 (2008) 435-477
24. Maccarrone M., Rossi S., Bari M., De Chiara V., Fezza F., Musella A., Gasperi V., Prosperetti C., Bernardi G., Finazzi-Agrò A., Cravatt B.F., and Centonze D. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat. Neurosci. 11 (2008) 152-159
25. + channel TASK-1. EMBO J. 20 (2001) 47-54
26. Marinelli S., Di Marzo V., Berretta N., Matias I., Maccarrone M., Bernardi G., and Mercuri N.B. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J. Neurosci. 23 (2003) 3136-3144
27. Marinelli S., Di Marzo V., Florenzano F., Fezza F., Viscomi M.T., van der Stelt M., Bernardi G., Molinari M., Maccarrone M., and Mercuri N.B. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 32 (2007) 298-308
28. 1 in the VTA excites dopaminergic neurons and increases chemical- and noxious-induced dopamine release in the nucleus accumbens. Neuropsychopharmacology 30 (2005) 864-870
29. Mezey E., Tóth Z.E., Cortright D.N., Arzubi M.K., Krause J.E., Elde R., Guo A., Blumberg P.M., and Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 3655-3660
30. Musella A., De Chiara V., Rossi S., Prosperetti Ch., Bernardi G., Maccarrone M., and Centonze D. TRPV1 channels facilitate glutamate transmission in the striatum. Mol. Cell. Neurosci. 40 (2009) 89-97
31. 1 ion channel. In: Köfalvi A. (Ed). Cannabinoids and the Brain (2008), Springer US 101-130
32. 4 calcium entry channel: a paradigm for gating diversity. Am. J. Physiol. Cell Physiol. 286 (2004) 195-205
33. Pertwee R.G. GPR55: a new member of the cannabinoid receptor clan?. Br. J. Pharmacol. 152 (2007) 984-986
34. Raiteri L., and Raiteri M. Synaptosomes still viable after 25 years of superfusion. Neurochem. Res. 25 (2000) 1265-1274
35. h. J. Neurosci. 23 (2003) 10146-10153
36. 3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res. 995 (2004) 176-183
37. Salminen O., Murphy K.L., McIntosh J.M., Drago J., Marks M.J., Collins A.C., and Grady S.R. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 65 (2004) 1526-1535
38. Sanchez J.F., Krause J.E., and Cortright D.N. The distribution and regulation of vanilloid receptor VR1 and VR1 5′ splice variant RNA expression in rat. Neuroscience 107 (2001) 373-381
39. Starowicz K., Nigam S., and Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol. Ther. 114 (2007) 13-33
40. Stella N., Schweitzer P., and Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388 (1997) 773-778
41. Szabó T., Bíró T., Gonzalez A.F., Palkovits M., and Blumberg P.M. Pharmacological characterization of vanilloid receptor located in the brain. Brain Res. Mol. Brain Res. 98 (2002) 51-57
42. 1) in the adult rat brain. Brain Res. Mol. Brain Res. 135 (2005) 162-168
43. 1 through the external protonation site. Mol. Cell. Neurosci. 30 (2005) 207-217
44. Tzavara E.T., Li D.L., Moutsimilli L., Bisogno T., Di Marzo V., Phebus L.A., Nomikos G.G., and Giros B. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol. Psychiatry 59 (2006) 508-515
45. Uchigashima M., Narushima M., Fukaya M., Katona I., Kano M., and Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J. Neurosci. 27 (2007) 3663-3676
46. Zhou F.M., Wilson C.J., and Dani J.A. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J. Neurobiol. 53 (2002) 590-605